On September 1, 2026, Kazia Therapeutics announced preclinical data demonstrating that its lead asset, paxalisib, reduced tumor burden by 52% in microsatellite stable (MSS)/proficient mismatch repair (pMMR) colorectal cancer models and enhanced response to immunotherapy. The company plans to launch a five-arm Phase 2 clinical trial for this indication, with enrollment expected to begin in the first quarter of 2027. Additionally, Kazia reported preclinical evidence that paxalisib resensitized CDK4/6 inhibitor-resistant tumors in HR+/HER2- breast cancer models and announced an expansion of its ongoing triple-negative breast cancer trial to include a three-arm evaluation of paxalisib combinations in this population. First patient enrollment for the breast cancer expansion is targeted before year-end 2026, with full enrollment anticipated by the end of 2027. Kazia Therapeutics operates as an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology and restore anti-tumor immunity.

On August 28, 2026, Kazia Therapeutics Limited priced an underwritten public offering of 2,580,000 American Depositary Shares (ADSs), each representing 500 ordinary shares. The offering includes pre-funded warrants to purchase up to 303,200 ADSs and accompanying Series A and Series B Warrants to purchase up to 2,243,478 and 2,064,000 ADSs, respectively. The combined public offering price is $15.50 per ADS and accompanying warrants, generating expected gross proceeds of approximately $40 million for the company. Additional potential gross proceeds of up to $80 million may be realized upon exercise of the Series A and B Warrants at prices of $17.825 and $19.375 per ADS. The net proceeds are intended to fund clinical development of paxalisib, including Phase 1b trials in advanced triple-negative breast cancer and expansions into HR+/HER2- breast cancer, as well as for working capital. The offering closed on or about August 31, 2026. Kazia Therapeutics is an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology.

Kazia Therapeutics Limited filed a prospectus supplement on August 28, 2026, reducing the maximum aggregate offering price of American Depositary Shares under its March 17, 2026 Sales Agreement with Leerink Partners LLC from $100 million to $80 million. This adjustment modifies the existing registration statement on Form F-3 (File No. 333-294392). The company operates in the biotechnology industry, focusing on the development of therapeutic treatments for cancer.

Kazia Therapeutics reported that its lead asset, paxalisib, achieved a 100% clinical benefit rate in six evaluable patients with Stage IV triple-negative breast cancer. Five patients demonstrated an objective response, including one complete metabolic response and four partial responses, while the sixth patient experienced stable disease. The treatment showed no serious adverse events related to paxalisib and resulted in median reductions of 83% in circulating tumor cell clusters and 51% in terminally exhausted T cells. Enrollment in the Phase 1b trial is expected to complete by July 2027. Kazia Therapeutics Limited operates as an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology.

Kazia Therapeutics Limited announced the filing of a provisional patent application for a novel therapeutic strategy designed to prevent metastatic recurrence in patients with high-risk early-stage triple-negative breast cancer. The filing is supported by preclinical data from a model replicating high-risk early-stage TNBC, where adjuvant paxalisib reduced residual disease and local recurrence by 95% and lung metastatic burden by 40%. Complementary translational studies on patient tumor samples showed paxalisib completely disrupted circulating tumor cell clusters. These findings, combined with encouraging preliminary data from an ongoing Phase Ib study in advanced metastatic TNBC, strengthen the rationale for advancing paxalisib across multiple disease stages. The company is actively evaluating opportunities to broaden clinical development into earlier-stage TNBC and expects to provide additional details on its development strategy in the near term. Kazia Therapeutics is an oncology-focused biotechnology company developing therapies that reprogram cancer biology and restore anti-tumor immunity.